Enhancement of taxane-based chemotherapy by a CDK1 antagonist

Details Enhancement of taxane-based chemotherapy by a CDK1 antagonist Enhancement of taxane-based chemotherapy by a CDK1 antagonist

2005-09-27

2005-09-27

Cook, Rebecca (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S449000

Reexamination Certificate

active

06949558

ABSTRACT:
The present invention provides a combination therapy for inhibiting the growth of tumor, for treating cancer, and for inducing cell death. The therapy comprises the sequential administration of taxane and a CDK1 antagonist. The present invention also provides pharmaceutical compositions comprising taxane and a CDK1 antagonist and kits comprising taxane and CDK1 antagonist.

REFERENCES:
patent: 6235776 (2001-05-01), Pamukcu et al.
patent: 6262054 (2001-07-01), Fennelly et al.
Altieri (2001) “The molecular basis and potential role of survivin in cancer diagnosis and therapy,”Trends Mol Med7:542-547.
Ambrosini et al (1997) “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,”Nat Med3: 917-921.
Chadebech et al. (2000) “Up-regulation of cdc2 protein during paclitaxel-induced apoptosis,”Int J Cancer87:779-786.
Grossman et al. (2000) “Inhibition of melanoma tumor growth in vivo by survivin targeting,”Proc Natl Acad Sci U S A98: 635-640.
Itzhaki et al. (1997) “Construction by gene targeting in human cells of a conditional CDC2 mutant that replicates its DNA,”Nat Gen15:258-265.
Li et al. (1999) “Pleiotropic cell-division defects and apoptosis induced by interference with survivin function,”Nat Cell Biolog1:461-466.
Motwani et al. (1999) “Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells,”Clin Cancer Res5:1876-18783.
O'Connor et al. (2000) “Regulation of apoptosis at cell division by p34cdc2phosphorylation of survivin,”Proc Natl Acad Sci U S A97:13103-13107.
Rudner et al. (1996) “The spindle assembly checkpoint,”Curr Opin Cell Biol8: 773-780.
Schwarz et al. (1999) “Cell cycle targets p53, cyclins, cyclin-dependent kinases,”Clin. Cancer Res.5 (Suppl) A122 (Abstract).
Shimizu et al. (1995) “Unscheduled activation of cyclin B1 Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage,”Cancer Res55:228-231.
Sorger et al. (1997) “Coupling cell division and cell death to microtubule dynamics,”Current Opinion in Cell Biology9:807-814.
Vandre et al. (1989) “Anaphase onset and dephosphorylation of mitotic phosphoproteins occur concomitantly,”J Cell Sci94:245-258.

Affiliated with

Also associated with

Rating

Enhancement of taxane-based chemotherapy by a CDK1 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of taxane-based chemotherapy by a CDK1 antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of taxane-based chemotherapy by a CDK1 antagonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3372864